James Irving

This profile gathers the share dealings of James Irving in Abattis Bioceuticals Corp. Over a trading history stretching from 16 September 2015 to 1 August 2018, the count stands at 21 filings.

On the open market, the record shows 1 purchase and 11 sales worth €168k. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 6 share grants. In 2018 alone, the filings show no purchases and 1 sale.

The newest entry dates from 3 August 2018: an open-market sale of €23k, in Abattis Bioceuticals Corp. The latest purchase dates back some time: it was published 3,846 days ago, on 13 April 2016. Filings reach the SEDI feed a median of 3 days after the trade. Until a filing is published, the market cannot know about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.